Investing in Life Science Innovation

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Learn more

Home
About Us
Team
Senior Advisors
Portfolio
News
Events
ESG Policy
Contact

Main Content

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
Following Pre-NDA Meeting with FDA

May 27, 2021

COVID Innovations March 25th, 2021

March 25, 2021

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

March 22, 2021

Footer

About Us

We are creating sustainable value – for patients, the pharmaceutical industry and our investors. Since 1984, TVM Capital Life Science has invested in more than 130 life science companies in Europe, Canada and the United States, currently managing in excess of €900 million from more than 50 investors.

Our Team

TVM Capital Life Science operates with an integrated team from its offices in Montreal and Munich. Our mission is to invest in the development of exciting life science products and the growth of substantial companies in the field that are or aspire to be innovative leaders in their market segment.

Offices

TVM Capital GmbH
Munich, Germany

TVM Life Science Management GmbH
Munich, Germany

TVM Life Science Management Inc.
Montreal, Westmount, Canada

Member of

in